Literature DB >> 17665201

Study on enhancement of fibronectin-mediated bacillus Calmette-Guérin attachment to urinary bladder wall in rabbits.

Zhou-Jun Shen1, Yi Wang, Guo-Qing Ding, Chun-Wu Pan, Rong-Ming Zheng.   

Abstract

To clarify whether intravesical usage of fibrin clot stabilizer epsilon-aminocaproic acid (EACA) or p-aminomethyl benzoic acid (PAMBA) and different injuries enhance fibronectin (FN)-mediated bacillus Calmette-Guérin (BCG) attachment to bladder wall. Thirty New Zealand male white rabbits were randomly divided into five groups and the bladder wall of each rabbit was injured by electrocautery, cryocautery or knife cutting on left lateral wall, right lateral wall and posterior wall in different groups, respectively. Different drug was instilled into the bladder: Group A: pure PBS; B: PBS and radiolabeled BCG ((3)H-BCG); C: EACA and (3)H-BCG; D: PAMBA and (3)H-BCG; E: heparin and (3)H-BCG. After instillation, each injured and non-injured bladder wall were surgically harvested and digested. The quantity of BCG attachment was detected by liquid scintillation counter (scintillation times per min, STPM). Quantity of BCG attachment to injured bladder wall was significantly (P < 0.01) greater than that of non-injured one, no matter which injury was performed. The BCG attachment to bladder wall in Group C or Group D was significantly (P < 0.05) greater than that of Group B. The quantity of BCG attachment to bladder of Group E was significantly (P < 0.05) less than that of Group B, C and D, respectively. Intravesical instillation of fibrin clot stabilizer (PAMBA, EACA) enhances FN-mediated BCG attachment to bladder wall while heparin inhibits this process. Injuries; e.g., cutting, cryocautery or electrocautery of bladder wall can significantly increase BCG attachment to the bladder wall.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17665201     DOI: 10.1007/s00345-007-0198-z

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  33 in total

1.  Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.

Authors:  M A Hudson; J J Yuan; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1990-12       Impact factor: 7.450

2.  Internalization of bacille Calmette-Guerin by bladder tumor cells.

Authors:  M J Becich; S Carroll; T L Ratliff
Journal:  J Urol       Date:  1991-06       Impact factor: 7.450

3.  Characterization of the fibronectin binding motif for a unique mycobacterial fibronectin attachment protein, FAP.

Authors:  W Zhao; J S Schorey; R Groger; P M Allen; E J Brown; T L Ratliff
Journal:  J Biol Chem       Date:  1999-02-19       Impact factor: 5.157

4.  Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.

Authors:  A Böhle; D Jocham; P R Bock
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

5.  Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response.

Authors:  L R Kavoussi; E J Brown; J K Ritchey; T L Ratliff
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

6.  Systemic bacillus Calmette-Guerin infection in patients treated by intravesical BCG therapy for superficial bladder cancer.

Authors:  A Steg; C Leleu; B Debré; L Boccon-Gibod; D Sicard
Journal:  Prog Clin Biol Res       Date:  1989

7.  Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG.

Authors:  E O Haaff; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1986-10       Impact factor: 7.450

Review 8.  The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis.

Authors:  H G Wiker; M Harboe
Journal:  Microbiol Rev       Date:  1992-12

9.  Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.

Authors:  D L Lamm; D E Thor; S C Harris; J A Reyna; V D Stogdill; H M Radwin
Journal:  J Urol       Date:  1980-07       Impact factor: 7.450

10.  Influence of fibrin clot inhibitors on the efficacy of intravesical Bacillus Calmette-Guérin in the treatment of superficial bladder cancer. The Dutch Southeast Cooperative Urological Group.

Authors:  J A Witjes; A P vd Meijden; W Doesburg; F M Debruyne
Journal:  Eur Urol       Date:  1993       Impact factor: 20.096

View more
  6 in total

Review 1.  Effect of anticoagulants and antiplatelet agents on the efficacy of intravesical BCG treatment of bladder cancer: A systematic review.

Authors:  Nader Fahmy; Alejandro Lazo-Langner; Alla E Iansavichene; Stephen E Pautler
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

2.  Current animal models of bladder cancer: Awareness of translatability (Review).

Authors:  Jie Ding; Ding Xu; Chunwu Pan; Min Ye; Jian Kang; Qiang Bai; Jun Qi
Journal:  Exp Ther Med       Date:  2014-07-11       Impact factor: 2.447

Review 3.  Insights from animal models of bladder cancer: recent advances, challenges, and opportunities.

Authors:  Bincy Anu John; Neveen Said
Journal:  Oncotarget       Date:  2017-05-09

4.  Establishment of an optimized orthotopic bladder cancer model in mice.

Authors:  Jinming Cai; Zhiwen Xie; Yilin Yan; Zhengnan Huang; Pengfei Tang; Xiangqian Cao; Zeyi Wang; Chenkai Yang; Mingyue Tan; Fang Zhang; Bing Shen
Journal:  BMC Urol       Date:  2022-09-03       Impact factor: 2.090

5.  Growth inhibition of HeLa cell by internalization of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) Tokyo.

Authors:  Akira Kitamura; Sohkichi Mastumoto; Izumi Asahina
Journal:  Cancer Cell Int       Date:  2009-12-02       Impact factor: 5.722

Review 6.  Animal Models in Bladder Cancer.

Authors:  Traian Constantin; Mihai Păvălean; Ștefana Bucur; Maria Magdalena Constantin; Alin Codruț Nicolescu; Irina Pacu; Victor Mădan
Journal:  Biomedicines       Date:  2021-11-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.